Wang et al. demonstrated that triptolide with 0.1, 0.3, or 1 mg/kg/day for 20 weeks inhibited colitis-related colon cancer progression in vivo via downregulating Rac1 and the Janus kinase (JAK)/STAT3 pathway (Wang et al., 2009). The gene discussed is STAT3; the disease is colitis.